In summary, BNP and calcium levels were significantly elevated while zinc was significantly reduced in T2DM patients with cardiovascular complication. Results from the study also shown positive correlation between BNP, calcium, Troponin-I levels and blood pressure. However, further longitudinal studies required to confirm these findings (Diabetes Research and Clinical Practice)
Diabetes News
Tag: Type 2 Diabetes
Longitudinal evaluation of gastric emptying in type 2 diabetes
In patients with long-term type 2 diabetes, gastric emptying of solids and liquids does not usually become more delayed over time, and abnormally slow gastric emptying of solids may improve (Diabetes Research and Clinical Practice)
Discordance in risk factors for the progression of diabetic retinopathy and diabetic nephropathy in patients with type 2 diabetes mellitus
Average glycemia was significantly associated with progression of DR, whereas glycemic variability and dyslipidemia were significantly associated with progression of DN in type 2 diabetes mellitus (Journal of Diabetes Investigation)
Association between trabecular bone score and type 2 diabetes: a quantitative update of evidence
Patients with type 2 diabetes have a lower TBS than non-diabetic individuals, suggesting that TBS can be a useful measurement for the assessment of fracture risk in diabetic patients (Osteoporosis International)
Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
DDP-4i effectively reduced serum CRP levels and showed no stronger effect than traditional oral antidiabetic agents (Lipids in Health and Disease)
SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class
Cardiovascular outcomes trials investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies (BMC Endocrine Disorders)
Deintensification in older patients with type 2 diabetes: A systematic review of approaches, rates and outcomes
Available but limited evidence suggests that the benefits of deintensification outweigh the harm in older people with type 2 diabetes with or without comorbidities (Diabetes, Obesity and Metabolism)
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus
Compared with men developing T2DM, women with T2DM do not have a significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in prescribing should prompt heightened efforts to improve the standard and equity of diabetes mellitus care in women and men (Circulation)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years (NEJM)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
In this trial involving patients with type 2 diabetes, the cardiovascular risk profile of oral semaglutide was not inferior to that of placebo (NEJM)
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
In adults with IGT or recently diagnosed type 2 diabetes, interventions that improved β-cell function during active treatment failed to produce persistent benefits after treatment withdrawal. These observations suggest that continued intervention may be required to alter the progressive β-cell dysfunction in IGT or early type 2 diabetes (Diabetes Care)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors (Lancet)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
Dapagliflozin seemed to prevent and reduce progression of kidney disease compared with placebo inthis large and diverse population of patients with type 2 diabetes with and without established atheroscleroticcardiovascular disease, most of whom had preserved renal function (Lancet)
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes
In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile (Cardiovascular Diabetology)
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up
Participants with type 2 diabetes who had been randomly assigned to intensive glucose control for 5.6 years had a lower risk of cardiovascular events than those who received standard therapy only during the prolonged period in which the glycated hemoglobin curves were separated (NEJM)
Recruitment, retention, and training of people with type 2 diabetes as diabetes prevention mentors (DPM) to support a healthcare professional-delivered diabetes prevention program: the Norfolk Diabetes Prevention Study (NDPS)
Individuals with type 2 diabetes can be recruited, trained and retained as DPM in large numbers to support a group-based diabetes prevention program delivered by healthcare professionals. This volunteer model is low cost, and accesses the large type 2 diabetes population that shares a lifestyle experience with the target population. This is an attractive model for supporting diabetes prevention efforts (BMJ)
Glycaemic benefit of iGlarLixi in insulin‐naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan‐O randomized trial
These results suggest that iGlarLixi achieves superior glycaemic control compared with iGlar or Lixi alone in T2DM patients with HbA1c ≥9% or those inadequately controlled on two OADs (Diabetes, Obesity and Metabolism)
Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea
In T2DM patients who failed to achieve glycemic control with a combination of maximum dosages of metformin and SU, the beta-cell function declined compared to NGT subjects. However, the beta-cells were still responsive to SUs, which play a significant role in glycemic control (Diabetes, Metabolic Syndrome and Obesity)
Understanding the mechanisms of reversal of type 2 diabetes
Clinical and pathophysiological studies have shown type 2 diabetes to be a condition mainly caused by excess, yet reversible, fat accumulation in the liver and pancreas (The Lancet Diabetes & Endocrinology)
Implementation of Basal–Bolus Therapy in Type 2 Diabetes
Bolus insulin delivered by patch and pen using an algorithm-based weekly insulin dose titration significantly improved HbA1c in adults with type 2 diabetes, with improved subject and health care provider experience and preference for the patch (Diabetes Technology and Therapeutics)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 40
- Next Page »
Glycosmedia is also available as an App: